Linking extracellular matrix agrin to the hippo pathway in liver cancer and beyond

Cancers

Volumn 10, Issue 2, 2018, Pages

  Chakraborty, Sayan ^a   Hong, Wanjin ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Agrin; Cardiac regeneration; Extracellular matrix; Hippo pathway; Liver cancer; Mechanotransduction; Neuromuscular junctions; YAP TAZ

Indexed keywords

AGRIN; FOCAL ADHESION KINASE; GLYPICAN 3; HIPPO PROTEIN; INTEGRIN LINKED KINASE; P21 ACTIVATED KINASE 1; PROTEIN TAZ; PROTEIN YAP; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG;

CANCER GROWTH; CELL SPREADING; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE DELETION; HIPPO SIGNALING; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MECHANOTRANSDUCTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; REVIEW; TRANSCRIPTION INITIATION;

EID: 85042297531     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers10020045     Document Type: Review

References (131)

1. Lu, P.; Weaver, V.M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395–406. [CrossRef] [PubMed]
2. Pickup, M.W.; Mouw, J.K.; Weaver, V.M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014, 15, 1243–1253. [CrossRef] [PubMed]
3. Chen, C.S.; Mrksich, M.; Huang, S.; Whitesides, G.M.; Ingber, D.E. Geometric control of cell life and death. Science 1997, 276, 1425–1428. [CrossRef] [PubMed]
4. Folkman, J.; Moscona, A. Role of cell shape in growth control. Nature 1978, 273, 345–349. [CrossRef] [PubMed]
5. Vogel, V.; Sheetz, M. Local force and geometry sensing regulate cell functions. Nat. Rev. Mol. Cell Biol. 2006, 7, 265–275. [CrossRef] [PubMed]
6. Bissell, M.J.; Hines, W.C. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17, 320–329. [CrossRef] [PubMed]
7. Butcher, D.T.; Alliston, T.; Weaver, V.M. A tense situation: Forcing tumour progression. Nat. Rev. Cancer 2009, 9, 108–122. [CrossRef] [PubMed]
8. Dong, J.; Feldmann, G.; Huang, J.; Wu, S.; Zhang, N.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.; Maitra, A.; Pan, D. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 2007, 130, 1120–1133. [CrossRef] [PubMed]
9. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giulitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474, 179–183. [CrossRef] [PubMed]
10. Aragona, M.; Panciera, T.; Manfrin, A.; Giulitti, S.; Michielin, F.; Elvassore, N.; Dupont, S.; Piccolo, S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013, 154, 1047–1059. [CrossRef] [PubMed]
11. Panciera, T.; Azzolin, L.; Cordenonsi, M.; Piccolo, S. Mechanobiology of YAP and TAZ in physiology and disease. Nat. Rev. Mol. Cell Biol. 2017, 18, 758–770. [CrossRef] [PubMed]
12. Fulford, A.; Tapon, N.; Ribeiro, P.S. Upstairs, downstairs: Spatial regulation of hippo signalling. Curr. Opin. Cell Biol. 2017, 51, 22–32. [CrossRef] [PubMed]
13. Hong, W.; Guan, K.L. The yap and taz transcription co-activators: Key downstream effectors of the mammalian hippo pathway. Semin. Cell Dev. Biol. 2012, 23, 785–793. [CrossRef] [PubMed]
14. Meng, Z.; Moroishi, T.; Guan, K.L. Mechanisms of hippo pathway regulation. Genes Dev. 2016, 30, 1–17. [CrossRef] [PubMed]
15. Pan, D. The Hippo signaling pathway in development and cancer. Dev. Cell 2010, 19, 491–505. [CrossRef] [PubMed]
16. Piccolo, S.; Dupont, S.; Cordenonsi, M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol. Rev. 2014, 94, 1287–1312. [CrossRef] [PubMed]
17. Yu, F.X.; Zhao, B.; Guan, K.L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015, 163, 811–828. [CrossRef] [PubMed]
18. Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.Y.; Guan, K.L. A coordinated phosphorylation by lats and CK1 regulates YAP stability through SCF(β-TrCP). Genes Dev. 2010, 24, 72–85. [CrossRef] [PubMed]
19. Chan, S.W.; Lim, C.J.; Loo, L.S.; Chong, Y.F.; Huang, C.; Hong, W. Teads mediate nuclear retention of TAZ to promote oncogenic transformation. J. Biol. Chem. 2009, 284, 14347–14358. [CrossRef] [PubMed]
20. Stein, C.; Bardet, A.F.; Roma, G.; Bergling, S.; Clay, I.; Ruchti, A.; Agarinis, C.; Schmelzle, T.; Bouwmeester, T.; Schubeler, D.; et al. YAP1 exerts its transcriptional control via tead-mediated activation of enhancers. PLoS Genet. 2015, 11, e1005465. [CrossRef] [PubMed]
21. Vassilev, A.; Kaneko, K.J.; Shu, H.; Zhao, Y.; DePamphilis, M.L. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001, 15, 1229–1241. [CrossRef] [PubMed]
22. Zanconato, F.; Forcato, M.; Battilana, G.; Azzolin, L.; Quaranta, E.; Bodega, B.; Rosato, A.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 2015, 17, 1218–1227. [CrossRef] [PubMed]
23. Zhao, B.; Ye, X.; Yu, J.; Li, L.; Li, W.; Li, S.; Lin, J.D.; Wang, C.Y.; Chinnaiyan, A.M.; Lai, Z.C., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22, 1962–1971. [CrossRef] [PubMed]
24. Wu, S.; Liu, Y.; Zheng, Y.; Dong, J.; Pan, D. The TEAD/TEF family protein scalloped mediates transcriptional output of the hippo growth-regulatory pathway. Dev. Cell 2008, 14, 388–398. [CrossRef] [PubMed]
25. Pobbati, A.V.; Hong, W. Emerging roles of tead transcription factors and its coactivators in cancers. Cancer Biol. Ther. 2013, 14, 390–398. [CrossRef] [PubMed]
26. Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP/TAZ at the roots of cancer. Cancer Cell 2016, 29, 783–803. [CrossRef] [PubMed]
27. Harvey, K.F.; Zhang, X.; Thomas, D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13, 246–257. [CrossRef] [PubMed]
28. Azzolin, L.; Panciera, T.; Soligo, S.; Enzo, E.; Bicciato, S.; Dupont, S.; Bresolin, S.; Frasson, C.; Basso, G.; Guzzardo, V.; et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 2014, 158, 157–170. [CrossRef] [PubMed]
29. Fan, R.; Kim, N.G.; Gumbiner, B.M. Regulation of hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl. Acad. Sci. USA 2013, 110, 2569–2574. [CrossRef] [PubMed]
30. Yu, F.X.; Luo, J.; Mo, J.S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W., et al. Mutant GQ/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25, 822–830. [CrossRef] [PubMed]
31. Yu, F.X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.; Yuan, H.; Tumaneng, K.; Li, H., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150, 780–791. [CrossRef] [PubMed]
32. Heidary Arash, E.; Song, K.M.; Song, S.; Shiban, A.; Attisano, L. Arhgef7 promotes activation of the Hippo pathway core kinase lats. EMBO J. 2014, 33, 2997–3011. [CrossRef] [PubMed]
33. Hu, J.K.; Du, W.; Shelton, S.J.; Oldham, M.C.; DiPersio, C.M.; Klein, O.D. An FAK-YAP-mTOR signaling axis regulates stem cell-based tissue renewal in mice. Cell Stem Cell 2017, 21, 91–106.e6. [CrossRef] [PubMed]
34. Sorrentino, G.; Ruggeri, N.; Zannini, A.; Ingallina, E.; Bertolio, R.; Marotta, C.; Neri, C.; Cappuzzello, E.; Forcato, M.; Rosato, A.; et al. Glucocorticoid receptor signalling activates YAP in breast cancer. Nat. Commun. 2017, 8, 14073. [CrossRef] [PubMed]
35. Wada, K.; Itoga, K.; Okano, T.; Yonemura, S.; Sasaki, H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138, 3907–3914. [CrossRef] [PubMed]
36. Kim, N.; Stiegler, A.L.; Cameron, T.O.; Hallock, P.T.; Gomez, A.M.; Huang, J.H.; Hubbard, S.R.; Dustin, M.L.; Burden, S.J. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135, 334–342. [CrossRef] [PubMed]
37. Zhang, B.; Luo, S.; Wang, Q.; Suzuki, T.; Xiong, W.C.; Mei, L. Lrp4 serves as a coreceptor of Agrin. Neuron 2008, 60, 285–297. [CrossRef] [PubMed]
38. Bezakova, G.; Ruegg, M.A. New insights into the roles of Agrin. Nat. Rev. Mol. Cell Biol. 2003, 4, 295–308. [CrossRef] [PubMed]
39. Gautam, M.; Noakes, P.G.; Moscoso, L.; Rupp, F.; Scheller, R.H.; Merlie, J.P.; Sanes, J.R. Defective neuromuscular synaptogenesis in Agrin-deficient mutant mice. Cell 1996, 85, 525–535. [CrossRef]
40. Zhang, W.; Coldefy, A.S.; Hubbard, S.R.; Burden, S.J. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J. Biol. Chem. 2011, 286, 40624–40630. [CrossRef] [PubMed]
41. McMahan, U.J.; Horton, S.E.; Werle, M.J.; Honig, L.S.; Kroger, S.; Ruegg, M.A.; Escher, G. Agrin isoforms and their role in synaptogenesis. Curr. Opin. Cell Biol. 1992, 4, 869–874. [CrossRef]
42. Sanes, J.R.; Lichtman, J.W. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat. Rev. Neurosci. 2001, 2, 791–805. [CrossRef] [PubMed]
43. Zong, Y.; Zhang, B.; Gu, S.; Lee, K.; Zhou, J.; Yao, G.; Figueiredo, D.; Perry, K.; Mei, L.; Jin, R. Structural basis of Agrin-Lrp4-MuSK signaling. Genes Dev. 2012, 26, 247–258. [CrossRef] [PubMed]
44. Lin, L.; McCroskery, S.; Ross, J.M.; Chak, Y.; Neuhuber, B.; Daniels, M.P. Induction of filopodia-like protrusions by transmembrane Agrin: Role of Agrin glycosaminoglycan chains and Rho-family gtpases. Exp. Cell Res. 2010, 316, 2260–2277. [CrossRef] [PubMed]
45. Denzer, A.J.; Brandenberger, R.; Gesemann, M.; Chiquet, M.; Ruegg, M.A. Agrin binds to the nerve-muscle basal lamina via laminin. J. Cell Biol. 1997, 137, 671–683. [CrossRef] [PubMed]
46. Tatrai, P.; Dudas, J.; Batmunkh, E.; Mathe, M.; Zalatnai, A.; Schaff, Z.; Ramadori, G.; Kovalszky, I. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab. Invest. 2006, 86, 1149–1160. [CrossRef] [PubMed]
47. Chakraborty, S.; Lakshmanan, M.; Swa, H.L.; Chen, J.; Zhang, X.; Ong, Y.S.; Loo, L.S.; Akincilar, S.C.; Gunaratne, J.; Tergaonkar, V.; et al. An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat. Commun. 2015, 6, 6184. [CrossRef] [PubMed]
48. Zender, L.; Spector, M.S.; Xue, W.; Flemming, P.; Cordon-Cardo, C.; Silke, J.; Fan, S.T.; Luk, J.M.; Wigler, M.; Hannon, G.J.; et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125, 1253–1267. [CrossRef] [PubMed]
49. Camargo, F.D.; Gokhale, S.; Johnnidis, J.B.; Fu, D.; Bell, G.W.; Jaenisch, R.; Brummelkamp, T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17, 2054–2060. [CrossRef] [PubMed]
50. Shen, S.; Guo, X.; Yan, H.; Lu, Y.; Ji, X.; Li, L.; Liang, T.; Zhou, D.; Feng, X.H.; Zhao, J.C., et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 2015, 25, 997–1012. [CrossRef] [PubMed]
51. Hicks-Berthet, J.; Varelas, X. Integrin-FAK-CDC42-PP1A signaling gnaws at YAP/TAZ activity to control incisor stem cells. Bioessays 2017, 39. [CrossRef] [PubMed]
52. Kim, N.G.; Gumbiner, B.M. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J. Cell Biol. 2015, 210, 503–515. [CrossRef] [PubMed]
53. Schwartz, M.A. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb. Perspect. Biol. 2010, 2, a005066. [CrossRef] [PubMed]
54. Chakraborty, S.; Njah, K.; Pobbati, A.V.; Lim, Y.B.; Raju, A.; Lakshmanan, M.; Tergaonkar, V.; Lim, C.T.; Hong, W. Agrin as a mechanotransduction signal regulating YAP through the Hippo pathway. Cell Rep. 2017, 18, 2464–2479. [CrossRef] [PubMed]
55. Xiong, W.C.; Mei, L. Agrin to YAP in cancer and neuromuscular junctions. Trends Cancer 2017, 3, 247–248. [CrossRef] [PubMed]
56. Wang, W.; Huang, J.; Chen, J. Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 2011, 286, 4364–4370. [CrossRef] [PubMed]
57. Zhao, B.; Li, L.; Lu, Q.; Wang, L.H.; Liu, C.Y.; Lei, Q.; Guan, K.L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011, 25, 51–63. [CrossRef] [PubMed]
58. Chan, S.W.; Lim, C.J.; Guo, F.; Tan, I.; Leung, T.; Hong, W. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J. Biol. Chem. 2013, 288, 37296–37307. [CrossRef] [PubMed]
59. Dai, X.; She, P.; Chi, F.; Feng, Y.; Liu, H.; Jin, D.; Zhao, Y.; Guo, X.; Jiang, D.; Guan, K.L.; et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J. Biol. Chem. 2013, 288, 34041–34051. [CrossRef] [PubMed]
60. Mana-Capelli, S.; Paramasivam, M.; Dutta, S.; McCollum, D. Angiomotins link F-actin architecture to Hippo pathway signaling. Mol. Biol. Cell 2014, 25, 1676–1685. [CrossRef] [PubMed]
61. Paramasivam, M.; Sarkeshik, A.; Yates, J.R., 3rd; Fernandes, M.J.; McCollum, D. Angiomotin family proteins are novel activators of the Lats2 kinase tumor suppressor. Mol. Biol. Cell 2011, 22, 3725–3733. [CrossRef] [PubMed]
62. Basu, S.; Totty, N.F.; Irwin, M.S.; Sudol, M.; Downward, J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 2003, 11, 11–23. [CrossRef]
63. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21, 2747–2761. [CrossRef] [PubMed]
64. Liu, C.Y.; Zha, Z.Y.; Zhou, X.; Zhang, H.; Huang, W.; Zhao, D.; Li, T.; Chan, S.W.; Lim, C.J.; Hong, W.; et al. The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the Scfβ-TrCP E3 ligase. J. Biol. Chem. 2010, 285, 37159–37169. [CrossRef] [PubMed]
65. Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moeendarbary, E.; Charras, G.; et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 2013, 15, 637–646. [CrossRef] [PubMed]
66. Chang, T.T.; Thakar, D.; Weaver, V.M. Force-dependent breaching of the basement membrane. Matrix Biol. 2017, 57–58, 178–189. [CrossRef] [PubMed]
67. Halder, G.; Dupont, S.; Piccolo, S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 2012, 13, 591–600. [CrossRef] [PubMed]
68. Elosegui-Artola, A.; Andreu, I.; Beedle, A.E.M.; Lezamiz, A.; Uroz, M.; Kosmalska, A.J.; Oria, R.; Kechagia, J.Z.; Rico-Lastres, P.; Le Roux, A.L.; et al. Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell 2017, 171, 1397–1410.e14. [CrossRef] [PubMed]
69. Yimlamai, D.; Fowl, B.H.; Camargo, F.D. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J. Hepatol. 2015, 63, 1491–1501. [CrossRef] [PubMed]
70. Gesemann, M.; Brancaccio, A.; Schumacher, B.; Ruegg, M.A. Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue. J. Biol. Chem. 1998, 273, 600–605. [CrossRef] [PubMed]
71. Jayadev, R.; Sherwood, D.R. Basement membranes. Curr. Biol. 2017, 27, R207–R211. [CrossRef] [PubMed]
72. Lv, X.; Fang, C.; Yin, R.; Qiao, B.; Shang, R.; Wang, J.; Song, W.; He, Y.; Chen, Y. Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget 2017, 8, 105340–105355. [CrossRef] [PubMed]
73. Winzen, U.; Cole, G.J.; Halfter, W. Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J. Biol. Chem. 2003, 278, 30106–30114. [CrossRef] [PubMed]
74. Parekh, A.; Ruppender, N.S.; Branch, K.M.; Sewell-Loftin, M.K.; Lin, J.; Boyer, P.D.; Candiello, J.E.; Merryman, W.D.; Guelcher, S.A.; Weaver, A.M. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys. J. 2011, 100, 573–582. [CrossRef] [PubMed]
75. Alexander, N.R.; Branch, K.M.; Parekh, A.; Clark, E.S.; Iwueke, I.C.; Guelcher, S.A.; Weaver, A.M. Extracellular matrix rigidity promotes invadopodia activity. Curr. Biol. 2008, 18, 1295–1299. [CrossRef] [PubMed]
76. shc couples mechanical signals to Rhoa through FAK-dependent recruitment of p115-RhoGEF and GEF-H1. Mol. Cell Biol. 2016, 36, 2824–2837. [CrossRef] [PubMed]
77. Mannaerts, I.; Leite, S.B.; Verhulst, S.; Claerhout, S.; Eysackers, N.; Thoen, L.F.; Hoorens, A.; Reynaert, H.; Halder, G.; van Grunsven, L.A. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 2015, 63, 679–688. [CrossRef] [PubMed]
78. Chang, C.; Goel, H.L.; Gao, H.; Pursell, B.; Shultz, L.D.; Greiner, D.L.; Ingerpuu, S.; Patarroyo, M.; Cao, S.; Lim, E.; et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells. Genes Dev. 2015, 29, 1–6. [CrossRef] [PubMed]
79. Elbediwy, A.; Vincent-Mistiaen, Z.I.; Spencer-Dene, B.; Stone, R.K.; Boeing, S.; Wculek, S.K.; Cordero, J.; Tan, E.H.; Ridgway, R.; Brunton, V.G.; et al. Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development 2016, 143, 1674–1687. [CrossRef] [PubMed]
80. Tang, Y.; Rowe, R.G.; Botvinick, E.L.; Kurup, A.; Putnam, A.J.; Seiki, M.; Weaver, V.M.; Keller, E.T.; Goldstein, S.; Dai, J.; et al. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev. Cell 2013, 25, 402–416. [CrossRef] [PubMed]
81. Wong, K.F.; Liu, A.M.; Hong, W.; Xu, Z.; Luk, J.M. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget 2016, 7, 77683–77695. [CrossRef] [PubMed]
82. Nardone, G.; Oliver-De La Cruz, J.; Vrbsky, J.; Martini, C.; Pribyl, J.; Skladal, P.; Pesl, M.; Caluori, G.; Pagliari, S.; Martino, F., et al. YAP regulates cell mechanics by controlling focal adhesion assembly. Nat. Commun. 2017, 8, 15321. [CrossRef] [PubMed]
83. Serrano, I.; McDonald, P.C.; Lock, F.; Muller, W.J.; Dedhar, S. Inactivation of the hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun. 2013, 4, 2976. [CrossRef] [PubMed]
84. Hamaratoglu, F.; Willecke, M.; Kango-Singh, M.; Nolo, R.; Hyun, E.; Tao, C.; Jafar-Nejad, H.; Halder, G. The tumour-suppressor genes NF2/merlin and expanded act through hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 2006, 8, 27–36. [CrossRef] [PubMed]
85. Asthagiri, A.R.; Parry, D.M.; Butman, J.A.; Kim, H.J.; Tsilou, E.T.; Zhuang, Z.; Lonser, R.R. Neurofibromatosis type 2. Lancet 2009, 373, 1974–1986. [CrossRef]
86. Rouleau, G.A.; Merel, P.; Lutchman, M.; Sanson, M.; Zucman, J.; Marineau, C.; Hoang-Xuan, K.; Demczuk, S.; Desmaze, C.; Plougastel, B.; et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993, 363, 515–521. [CrossRef] [PubMed]
87. Trofatter, J.A.; MacCollin, M.M.; Rutter, J.L.; Murrell, J.R.; Duyao, M.P.; Parry, D.M.; Eldridge, R.; Kley, N.; Menon, A.G.; Pulaski, K., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 72, 791–800. [CrossRef]
88. Yin, F.; Yu, J.; Zheng, Y.; Chen, Q.; Zhang, N.; Pan, D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154, 1342–1355. [CrossRef] [PubMed]
89. Li, Y.; Zhou, H.; Li, F.; Chan, S.W.; Lin, Z.; Wei, Z.; Yang, Z.; Guo, F.; Lim, C.J.; Xing, W.; et al. Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. Cell Res. 2015, 25, 801–817. [CrossRef] [PubMed]
90. Das, T.; Safferling, K.; Rausch, S.; Grabe, N.; Boehm, H.; Spatz, J.P. A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat. Cell Biol. 2015, 17, 276–287. [CrossRef] [PubMed]
91. Levental, K.R.; Yu, H.; Kass, L.; Lakins, J.N.; Egeblad, M.; Erler, J.T.; Fong, S.F.; Csiszar, K.; Giaccia, A.; Weninger, W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139, 891–906. [CrossRef] [PubMed]
92. Okada, T.; You, L.; Giancotti, F.G. Shedding light on merlin’s wizardry. Trends Cell Biol. 2007, 17, 222–229. [CrossRef] [PubMed]
93. Sabra, H.; Brunner, M.; Mandati, V.; Wehrle Haller, B.; Lallemand, D.; Ribba, A.S.; Chevalier, G.; Guardiola, P.; Block, M.R.; Bouvard, D. β1 integrin dependent RAC/group I pak signaling mediates YAP activation of Yes associated protein 1 (YAP1) via NF2/Merlin. J. Biol. Chem. 2017, 19179–19197. [CrossRef] [PubMed]
94. Mazzon, C.; Anselmo, A.; Cibella, J.; Soldani, C.; Destro, A.; Kim, N.; Roncalli, M.; Burden, S.J.; Dustin, M.L.; Sarukhan, A.; et al. The critical role of agrin in the hematopoietic stem cell niche. Blood 2011, 118, 2733–2742. [CrossRef] [PubMed]
95. Anselmo, A.; Lauranzano, E.; Soldani, C.; Ploia, C.; Angioni, R.; D'Amico, G.; Sarukhan, A.; Mazzon, C.; Viola, A. Identification of a novel agrin-dependent pathway in cell signaling and adhesion within the erythroid niche. Cell Death Differ. 2016, 23, 1322–1330. [CrossRef] [PubMed]
96. Mohseni, M.; Sun, J.; Lau, A.; Curtis, S.; Goldsmith, J.; Fox, V.L.; Wei, C.; Frazier, M.; Samson, O.; Wong, K.K.; et al. A genetic screen identifies an LKB1-mark signalling axis controlling the Hippo-YAP pathway. Nat. Cell Biol. 2014, 16, 108–117. [CrossRef] [PubMed]
97. Edwards, D.N.; Ngwa, V.M.; Wang, S.; Shiuan, E.; Brantley-Sieders, D.M.; Kim, L.C.; Reynolds, A.B.; Chen, J. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci. Signal 2017, 10. [CrossRef] [PubMed]
98. Benham-Pyle, B.W.; Pruitt, B.L.; Nelson, W.J. Cell adhesion. Mechanical strain induces E-cadherin-dependent YAP1 and β-catenin activation to drive cell cycle entry. Science 2015, 348, 1024–1027. [CrossRef] [PubMed]
99. Fernandez, B.G.; Gaspar, P.; Bras-Pereira, C.; Jezowska, B.; Rebelo, S.R.; Janody, F. Actin-capping protein and the Hippo pathway regulate F-actin and tissue growth in drosophila. Development 2011, 138, 2337–2346. [CrossRef] [PubMed]
100. Sansores-Garcia, L.; Bossuyt, W.; Wada, K.; Yonemura, S.; Tao, C.; Sasaki, H.; Halder, G. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 2011, 30, 2325–2335. [CrossRef] [PubMed]
101. Meng, Z.; Moroishi, T.; Mottier-Pavie, V.; Plouffe, S.W.; Hansen, C.G.; Hong, A.W.; Park, H.W.; Mo, J.S.; Lu, W.; Lu, S., et al. MAP4K family kinases act in parallel to MST1/2 to activate Lats1/2 in the Hippo pathway. Nat. Commun. 2015, 6, 8357. [CrossRef] [PubMed]
102. Zhao, B.; Li, L.; Wang, L.; Wang, C.Y.; Yu, J.; Guan, K.L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012, 26, 54–68. [CrossRef] [PubMed]
103. Densham, R.M.; O’Neill, E.; Munro, J.; Konig, I.; Anderson, K.; Kolch, W.; Olson, M.F. MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol. Cell Biol. 2009, 29, 6380–6390. [CrossRef] [PubMed]
104. Visser-Grieve, S.; Zhou, Z.; She, Y.M.; Huang, H.; Cyr, T.D.; Xu, T.; Yang, X. Lats1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization. Cell Res. 2011, 21, 1513–1516. [CrossRef] [PubMed]
105. Rauskolb, C.; Sun, S.; Sun, G.; Pan, Y.; Irvine, K.D. Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex. Cell 2014, 158, 143–156. [CrossRef] [PubMed]
106. Wang, L.; Luo, J.Y.; Li, B.; Tian, X.Y.; Chen, L.J.; Huang, Y.; Liu, J.; Deng, D.; Lau, C.W.; Wan, S.; et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature 2016, 579. [CrossRef] [PubMed]
107. Sorrentino, G.; Ruggeri, N.; Specchia, V.; Cordenonsi, M.; Mano, M.; Dupont, S.; Manfrin, A.; Ingallina, E.; Sommaggio, R.; Piazza, S.; et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014, 16, 357–366. [CrossRef] [PubMed]
108. Guo, Y.; Pan, Q.; Zhang, J.; Xu, X.; Liu, X.; Wang, Q.; Yi, R.; Xie, X.; Yao, L.; Liu, W., et al. Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J. Cell Biochem. 2015, 116, 2465–2475. [CrossRef] [PubMed]
109. Han, S.X.; Bai, E.; Jin, G.H.; He, C.C.; Guo, X.J.; Wang, L.J.; Li, M.; Ying, X.; Zhu, Q. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J. Immunol. Res. 2014, 2014, 261365. [CrossRef] [PubMed]
110. Xu, M.Z.; Yao, T.J.; Lee, N.P.; Ng, I.O.; Chan, Y.T.; Zender, L.; Lowe, S.W.; Poon, R.T.; Luk, J.M. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115, 4576–4585. [CrossRef] [PubMed]
111. Kim, G.J.; Kim, H.; Park, Y.N. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS ONE 2013, 8, e75449. [CrossRef] [PubMed]
112. Xu, M.Z.; Chan, S.W.; Liu, A.M.; Wong, K.F.; Fan, S.T.; Chen, J.; Poon, R.T.; Zender, L.; Lowe, S.W.; Hong, W., et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011, 30, 1229–1240. [CrossRef] [PubMed]
113. Kim, W.; Khan, S.K.; Liu, Y.; Xu, R.; Park, O.; He, Y.; Cha, B.; Gao, B.; Yang, Y. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut 2017. [CrossRef] [PubMed]
114. Lee, K.P.; Lee, J.H.; Kim, T.S.; Kim, T.H.; Park, H.D.; Byun, J.S.; Kim, M.C.; Jeong, W.I.; Calvisi, D.F.; Kim, J.M.; et al. The Hippo-salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 8248–8253. [CrossRef] [PubMed]
115. Lu, L.; Li, Y.; Kim, S.M.; Bossuyt, W.; Liu, P.; Qiu, Q.; Wang, Y.; Halder, G.; Finegold, M.J.; Lee, J.S., et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 2010, 107, 1437–1442. [CrossRef] [PubMed]
116. Zhou, D.; Conrad, C.; Xia, F.; Park, J.S.; Payer, B.; Yin, Y.; Lauwers, G.Y.; Thasler, W.; Lee, J.T.; Avruch, J.; et al. MST1 and MST2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the YAP1 oncogene. Cancer Cell 2009, 16, 425–438. [CrossRef] [PubMed]
117. Kawahara, R.; Granato, D.C.; Carnielli, C.M.; Cervigne, N.K.; Oliveria, C.E.; Rivera, C.; Yokoo, S.; Fonseca, F.P.; Lopes, M.; Santos-Silva, A.R.; et al. Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. PLoS ONE 2014, 9, e115004. [CrossRef] [PubMed]
118. Hiemer, S.E.; Zhang, L.; Kartha, V.K.; Packer, T.S.; Almershed, M.; Noonan, V.; Kukuruzinska, M.; Bais, M.V.; Monti, S.; Varelas, X. A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. Mol. Cancer Res. 2015, 13, 957–968. [CrossRef] [PubMed]
119. Newton, Y.; Novak, A.M.; Swatloski, T.; McColl, D.C.; Chopra, S.; Graim, K.; Weinstein, A.S.; Baertsch, R.; Salama, S.R.; Ellrott, K.; et al. Tumormap: Exploring the molecular similarities of cancer samples in an interactive portal. Cancer Res. 2017, 77, e111–e114. [CrossRef] [PubMed]
120. Feng, M.; Gao, W.; Wang, R.; Chen, W.; Man, Y.G.; Figg, W.D.; Wang, X.W.; Dimitrov, D.S.; Ho, M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 2013, 110, E1083–E1091. [CrossRef] [PubMed]
121. Miao, H.L.; Pan, Z.J.; Lei, C.J.; Wen, J.Y.; Li, M.Y.; Liu, Z.K.; Qiu, Z.D.; Lin, M.Z.; Chen, N.P.; Chen, M. Knockdown of GPC3 inhibits the proliferation of HUH7 hepatocellular carcinoma cells through down-regulation of YAP. J. Cell Biochem. 2013, 114, 625–631. [CrossRef] [PubMed]
122. Baumhoer, D.; Tornillo, L.; Stadlmann, S.; Roncalli, M.; Diamantis, E.K.; Terracciano, L.M. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899–906. [CrossRef] [PubMed]
123. Zhu, Z.W.; Friess, H.; Wang, L.; Abou-Shady, M.; Zimmermann, A.; Lander, A.D.; Korc, M.; Kleeff, J.; Buchler, M.W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48, 558–564. [CrossRef] [PubMed]
124. Zhao, K.; Shen, C.; Lu, Y.; Huang, Z.; Li, L.; Rand, C.D.; Pan, J.; Sun, X.D.; Tan, Z.; Wang, H., et al. Muscle YAP is a regulator of neuromuscular junction formation and regeneration. J. Neurosci. 2017, 3465–3477. [CrossRef] [PubMed]
125. Legoix, P.; Bluteau, O.; Bayer, J.; Perret, C.; Balabaud, C.; Belghiti, J.; Franco, D.; Thomas, G.; Laurent-Puig, P.; Zucman-Rossi, J. β-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999, 18, 4044–4046. [CrossRef] [PubMed]
126. Bassat, E.; Mutlak, Y.E.; Genzelinakh, A.; Shadrin, I.Y.; Baruch Umansky, K.; Yifa, O.; Kain, D.; Rajchman, D.; Leach, J.; Riabov Bassat, D.; et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 2017, 547, 179–184. [CrossRef] [PubMed]
127. Gesemann, M.; Cavalli, V.; Denzer, A.J.; Brancaccio, A.; Schumacher, B.; Ruegg, M.A. Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the putative agrin receptor. Neuron 1996, 16, 755–767. [CrossRef]
128. Morikawa, Y.; Heallen, T.; Leach, J.; Xiao, Y.; Martin, J.F. Dystrophin-glycoprotein complex sequesters YAP to inhibit cardiomyocyte proliferation. Nature 2017, 547, 227–231. [CrossRef] [PubMed]
129. Suleiman, H.; Zhang, L.; Roth, R.; Heuser, J.E.; Miner, J.H.; Shaw, A.S.; Dani, A. Nanoscale protein architecture of the kidney glomerular basement membrane. eLife 2013, 2, e01149. [CrossRef] [PubMed]
130. Reginensi, A.; Scott, R.P.; Gregorieff, A.; Bagherie-Lachidan, M.; Chung, C.; Lim, D.S.; Pawson, T.; Wrana, J.; McNeill, H. YAP- and CDC42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 2013, 9, e1003380. [CrossRef] [PubMed]
131. Reginensi, A.; Enderle, L.; Gregorieff, A.; Johnson, R.L.; Wrana, J.L.; McNeill, H. A critical role for NF2 and the Hippo pathway in branching morphogenesis. Nat. Commun. 2016, 7, 12309. [CrossRef] [PubMed]